{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:19:38Z","timestamp":1790435978385,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jpha.2021.12.003","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T23:42:45Z","timestamp":1639698165000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review"],"prefix":"10.1016","volume":"12","author":[{"given":"Bhagat","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakant","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2021.12.003_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2021.12.003_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.dsx.2020.04.019","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.jpha.2021.12.003_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2021.12.003_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2021.12.003_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jpha.2021.12.003_bib6","article-title":"Preventing a COVID-19 pandemic","volume":"368","author":"Watkins","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jpha.2021.12.003_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.jpha.2021.12.003_bib8","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz","year":"2020","journal-title":"J.\u00a0Travel Med."},{"key":"10.1016\/j.jpha.2021.12.003_bib9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","article-title":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2","volume":"24","author":"Li","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.jpha.2021.12.003_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-03120-0","article-title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19","volume":"24","author":"Ni","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpha.2021.12.003_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.jpha.2021.12.003_bib12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 Pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-1\u20137\/MAS axis of the renin-angiotensin system: focus on angiotensin-1\u20137","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jpha.2021.12.003_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cardiores.2006.09.006","article-title":"ACE2 of the heart: from angiotensin I to angiotensin (1\u20137)","volume":"73","author":"Keidar","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jpha.2021.12.003_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5049\/EBP.2008.6.1.42","article-title":"Renin-angiotensin system - considerations for hypertension and kidney","volume":"6","author":"Yim","year":"2008","journal-title":"Electrol. Blood Pres."},{"key":"10.1016\/j.jpha.2021.12.003_bib16","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A\u00a0human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jpha.2021.12.003_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jpha.2021.12.003_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jpha.2021.12.003_bib19","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.jpha.2021.12.003_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.HYP.33.2.613","article-title":"Recent progress in angiotensin II type 2 receptor research in the cardiovascular system","volume":"33","author":"Horiuchi","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1161\/HYPERTENSIONAHA.117.09822","article-title":"Vascular ADAM 17 (a disintegrin and metalloproteinase domain 17) is required for angiotensin II\/\u03b2-aminopropionitrile-induced abdominal aortic aneurysm","volume":"70","author":"Kawai","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.116.07620","article-title":"Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II","volume":"68","author":"Takayanagi","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin-converting enzyme 2 (ACE2) in SARS coronavirus induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpha.2021.12.003_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.jpha.2021.12.003_bib25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jpha.2021.12.003_bib26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jpha.2021.12.003_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2021.12.003_bib28","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with a receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jpha.2021.12.003_bib29","doi-asserted-by":"crossref","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","article-title":"Ectodomain shedding of angiotensin-converting enzyme 2 in human airway epithelia","volume":"297","author":"Jia","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.jpha.2021.12.003_bib30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jpha.2021.12.003_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.jpha.2021.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-016-0234-7","article-title":"Surface vimentin is critical for the cell entry of SARS-CoV","volume":"23","author":"Yu","year":"2016","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.jpha.2021.12.003_bib33","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jpha.2021.12.003_bib34","doi-asserted-by":"crossref","first-page":"F487","DOI":"10.1152\/ajprenal.00074.2017","article-title":"Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease","volume":"313","author":"Wysocki","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.jpha.2021.12.003_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ccc.2018.11.002","article-title":"Classic and non-classic renin-angiotensin systems in the critically ill","volume":"35","author":"Bitker","year":"2019","journal-title":"Crit. Care Clin."},{"key":"10.1016\/j.jpha.2021.12.003_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.jpha.2021.12.003_bib38","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jpha.2021.12.003_bib39","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/cid\/cis733","article-title":"Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes","volume":"55","author":"Mortensen","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpha.2021.12.003_bib40","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin-converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2021.12.003_bib42","unstructured":"Y.-M. Yan, X. Shen, Y.-K. Cao, et al., Discovery of anti-2019-nCoV agents from Chinese patent drugs toward respiratory diseases via docking screening, Preprints. https:\/\/www.preprints.org\/manuscript\/202002.0254\/v1."},{"key":"10.1016\/j.jpha.2021.12.003_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/mol.111.076620","article-title":"Mechanisms of the inhibition of nuclear factor kappab by morphine in neuronal cells","volume":"81","author":"B\u00f6rner","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpha.2021.12.003_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin ii in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpha.2021.12.003_bib45","volume":"9","author":"Guo","year":"2020","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.jpha.2021.12.003_bib46","series-title":"Encyclopedia of Endocrine Diseases","article-title":"Interference with the renin-angiotensin aystem (RAS): classical inhibitors and novel approaches.","author":"Colafella","year":"2018"},{"key":"10.1016\/j.jpha.2021.12.003_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpha.2021.12.003_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpha.2021.12.003_bib49","doi-asserted-by":"crossref","first-page":"C279","DOI":"10.1152\/ajpcell.00478.2020","article-title":"Soluble ACE2 as a potential therapy for COVID-19","volume":"320","author":"Krishnamurthy","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.jpha.2021.12.003_bib50","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpha.2021.12.003_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2021.12.003_bib52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.jpha.2021.12.003_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","article-title":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS","volume":"39","author":"Oudit","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.jpha.2021.12.003_bib54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jpha.2021.12.003_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/postgradmedj-2020-137935","article-title":"ACE2 and COVID-19 and the resulting ARDS","volume":"96","author":"Zhang","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jpha.2021.12.003_bib56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jpha.2021.12.003_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000515232","article-title":"Outcomes of hospitalized COVID-19 patients receiving renin-angiotensin system blockers and calcium channel blockers","volume":"52","author":"Choksi","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.jpha.2021.12.003_bib58","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1099\/vir.0.043919-0","article-title":"Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63","volume":"93","author":"Dijkman","year":"2012","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.jpha.2021.12.003_bib59","first-page":"429","article-title":"Angiotensin-1 converting enzyme (ACE) inhibitory activity of peptides isolated from bovine milk fermented with Lactobacillus helveticus NCDC 288","volume":"66","author":"Singh","year":"2011","journal-title":"Milchwissenschaft"},{"key":"10.1016\/j.jpha.2021.12.003_bib60","first-page":"411","article-title":"Potential of novel bioactive peptides as functional food ingredients in preventing cardiovascular disease.","volume":"Vol. 17","author":"Singh","year":"2018"},{"key":"10.1016\/j.jpha.2021.12.003_bib61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jpha.2021.12.003_bib62","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.jpha.2021.12.003_bib63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5334\/gh.814","article-title":"The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis","volume":"15","author":"Matsushita","year":"2020","journal-title":"Glob. Heart"},{"key":"10.1016\/j.jpha.2021.12.003_bib64","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCRESAHA.121.318054","article-title":"Hypertension, a moving target in COVID-19: current views and perspectives","volume":"128","author":"Savoia","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.jpha.2021.12.003_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/HYPERTENSIONAHA.121.17328","article-title":"Discontinuation of antihypertensive medications on the outcome of hospitalized patients with severe acute respiratory- coronavirus 2","volume":"78","author":"Singh","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jpha.2021.12.003_bib66","series-title":"Highlights on Medicine and Medical Science,","first-page":"142","article-title":"A review on current status of SARS-CoV-2 (2019-nCoV): its diagnosis and challenges.","volume":"Vol. 14","author":"Singh","year":"2021"},{"key":"10.1016\/j.jpha.2021.12.003_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2021.12.003_bib68","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.jpha.2021.12.003_bib69","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.012","article-title":"Hexapeptide of the receptor-binding domain of SARS coronavirus spike protein blocks viral entry into host cells via the human receptor ACE2","volume":"94","author":"Struck","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jpha.2021.12.003_bib70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/science.368.6486.14","article-title":"Vaccine designers take first shots at COVID-19","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177921001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177921001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:33:34Z","timestamp":1761860014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177921001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2095177921001465"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2021.12.003","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}]}}